Skip to main content
. Author manuscript; available in PMC: 2015 Jan 1.
Published in final edited form as: Eur J Cancer. 2013 Nov 15;50(2):302–308. doi: 10.1016/j.ejca.2013.10.006

Table 5.

Overall Survival by Maximum Dose Level for Patients Developing Grade≥2 Rash

2-Month Landmark 4-Month Landmark
# of Events/N Median & 95% CI # of Events/N Median & 95% CI
Maximum Dose
≤150 30/30 7.2 (2.7, 16.2) 23/23 8.6 (2.5, 21.2)
>150 29/32 19/1 (9.6, 26.6) 27/30 18.3 (11.5, 25.0)
P 0.047 0.19